Pfizer Stock: A Critical Pivot Point

Pharmaceutical titan Pfizer finds itself at a pivotal juncture. The era of spectacular pandemic-driven profits is receding, and the company now contends with a challenging combination of stricter vaccine regulations and skittish investors. However, a new source of potential is emerging from its oncology division. The central question for the market is whether this will be sufficient to engineer a major turnaround or if shareholders should brace for further declines.

Looking beyond immediate pressures, Pfizer is actively positioning itself for future growth. In a significant move, its strategic partner in China, 3SBio, has raised approximately $400 million through a share placement. This capital injection is earmarked to accelerate research and could ultimately Read more...